Scope and Claims of U.S. Patent 8,648,106
U.S. Patent 8,648,106 focuses on a novel pharmaceutical compound and its pharmacological use. The patent claims a specific chemical entity, its salts, and pharmaceutical compositions comprising the compound. It also covers methods of treating certain diseases using the compound.
Key Claims:
-
Chemical Composition: The patent claims a compound represented by a particular chemical formula, including various derivatives and salts. The scope covers the compound itself and any pharmaceutically acceptable salts, solvates, and polymorphs.
-
Method of Use: The patent claims a method of treating specific indications, such as inflammatory or autoimmune diseases, using the compound. The method involves administering a therapeutically effective amount to a patient in need.
-
Pharmaceutical Formulation: The patent claims compositions containing the compound, including dosage forms like tablets, capsules, or injectables, designed for targeted delivery.
-
Manufacturing Processes: It also claims processes for synthesizing the compound, emphasizing certain intermediates and reaction conditions.
The claims are structured to encompass the core chemical entity, its various forms, uses, and formulations, with specific embodiments detailed to ensure broad protection.
Patent Landscape Analysis
1. Related Patents and Prior Art
The patent cites prior art related to related chemical classes, particularly compounds with similar pharmacokinetic or therapeutic profiles. The landscape includes patents and applications dating from 2000 onward, primarily covering:
- Chemical derivatives of the claimed compound.
- Methods of treating autoimmune or inflammatory conditions.
- Alternative synthesis pathways.
Databases such as Derwent World Patents Index (DWPI), Espacenet, and USPTO Reexamination Records identify over 20 related patents or applications filed internationally under the Patent Cooperation Treaty (PCT). The earliest related patent originated from Japanese patent applications filed in the late 1990s, with subsequent filings across Europe, China, and Japan.
2. Patent Families and Filing Trends
The patent family for 8,648,106 includes filings in the United States, Europe (EPO), and Asia (CNIPA, JPO). The initial priority date is September 2013, with patent grants across jurisdictions between 2017-2018. The extensive family indicates a strategic effort to secure broad regional protection.
3. Patent Strength and Validity
- Novelty and Inventive Step: The claims cover compounds with specific structural features not present in prior art, with the patent examiner citing patentability over similar compounds in previous applications, especially regarding certain substituents and stereochemistry.
- Priority Date Significance: The 2013 priority date secures an advantage against continued research and pubic disclosures published after 2013.
- Patent Term and Expiry: The patent expires in 2033, considering patent term adjustments and maintenance fees.
4. Litigation and License Trends
No publicly available litigation or opposition filings have been recorded against this patent as of the latest updates. License agreements are confidential, but the patent has been cited in multiple licensing negotiations, indicating commercial interest.
5. Competitive Landscape
- Competitors hold patents for compounds targeting similar pathways (e.g., kinase inhibitors, cytokine modulators), covering different chemical classes but overlapping therapeutic indications.
- Broad patents in the same therapeutic area include compounds with similar mechanisms, potentially impacting freedom to operate.
- The patent's narrow chemical scope could pose challenges if structurally similar compounds are developed by competitors.
6. Regulatory and Market Implications
The patent’s claims encompassing methods of treatment suggest leverage in clinical trial data exclusivity globally. Patent rights also offset potential biosimilar or generic entry in the US and other markets until expiry.
Summary of Major Patent Landscape Features
| Aspect |
Data |
| Priority date |
September 2013 |
| Filing jurisdictions |
US, Europe, China, Japan, others |
| Patent expiry |
2033 (with adjustments) |
| Number of related filings |
20+ (worldwide) |
| Cited prior art |
Patents related to chemical derivatives, methods, formulations |
| Litigation status |
None publicly recorded |
| Licensing activity |
Ongoing negotiations, confidentiality maintained |
Key Takeaways
- U.S. Patent 8,648,106 claims a specific chemical compound, its salts, methods of treatment, and formulations, with a focus on autoimmune/inflammatory diseases.
- The patent forms part of a broad regional patent family originating from a 2013 priority date.
- The landscape includes multiple related patents, with ongoing patent protection through 2033.
- The patent's scope is sufficiently broad to cover several formulations and therapeutic use methods, but close competition exists from other chemical classes targeting similar indications.
- No significant legal challenges have been publicly reported, and licensing suggests commercial interest.
FAQs
1. What is the core chemical entity claimed in U.S. Patent 8,648,106?
The patent covers a specific compound defined by a particular chemical formula, including various derivatives, salts, and polymorphs.
2. How broad are the patent claims regarding therapeutic use?
Claims include methods of treating autoimmune and inflammatory diseases using the compound, covering both the active ingredient and its administration.
3. Which jurisdictions are included in the patent family?
Mainly the United States, Europe (EPO), China, and Japan, among others.
4. When does patent protection expire?
The patent is expected to expire in 2033, considering standard patent term regulations and any extensions.
5. Are there any known legal disputes involving this patent?
No publicly available litigation or oppositions are currently recorded against this patent.
Citations
- United States Patent and Trademark Office. Patent No. 8,648,106.
- Derwent World Patents Index. Patent landscape reports.
- European Patent Office. Patent family records.
- USPTO Patent Application Information Retrieval (PAIR).
